Lenz Therapeutics Announces Licensing Agreement Milestone With Lotus for VIZZ in South Korea and Southeast Asia
I'm PortAI, I can summarize articles.
Lenz Therapeutics announced a milestone in its licensing agreement with Lotus Pharmaceutical, as Lotus submitted a New Drug Application for VIZZ in South Korea. The agreement, signed in May 2025, covers South Korea and Southeast Asia, with Lenz eligible for up to $125 million in milestone payments and royalties. Lotus holds exclusive rights for VIZZ's development and commercialization in these regions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments